Latest filing published 17 Apr 2025 for Immunovant, Inc., €109k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Peter Salzmann: trading record in brief
Peter Salzmann, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Immunovant, Inc. and Corbus Pharmaceuticals Holdings, Inc. We count 48 filings; the first trade dates from 19 March 2021 and the latest from 16 April 2025.
The open-market record consists of 41 sales worth €11.7M, with no purchase. The rest of the record consists of 7 share grants. Since January 2025: no purchases and 6 sales on the market.
The record was last updated on 17 April 2025 with an open-market sale (€109k) in Immunovant, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Peter Salzmann
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 8,321 shares@ US$14.890.9% of flowCommon StockSEC:0001764013-25-000075:0
- 28,094 shares@ US$12.992.8% of flowCommon StockSEC:0001764013-25-000066:0
- 265,820 shares0Common StockSEC:0001764013-25-000049:0
- 15,439 shares@ US$20.862.6% of flowCommon StockSEC:0001764013-25-000030:0
- 8,352 shares@ US$23.811.6% of flowCommon StockSEC:0001764013-25-000013:0
- 5,105 shares@ US$24.101.0% of flowCommon StockSEC:0001764013-25-000003:0
- 16,692 shares@ US$25.453.4% of flowCommon StockSEC:0001764013-24-000193:0
- 9,095 shares@ US$28.792.1% of flowCommon StockSEC:0001764013-24-000174:0
- 4,460 shares@ US$29.561.0% of flowCommon StockSEC:0001764013-24-000165:0
- 14,470 shares@ US$31.843.5% of flowCommon StockSEC:0001764013-24-000156:0
- 8,175 shares@ US$29.641.9% of flowCommon StockSEC:0001764013-24-000133:0
- 4,619 shares@ US$28.061.0% of flowCommon StockSEC:0001764013-24-000125:0
- 2,783 shares0Common Stock, par value $0.0001 per shareSEC:0000950170-24-068030:0
- 16,163 shares@ US$29.653.8% of flowCommon StockSEC:0001764013-24-000098:0
- 26,365 shares@ US$28.806.1% of flowCommon StockSEC:0001764013-24-000075:0
- 4,807 shares@ US$31.181.2% of flowCommon StockSEC:0001764013-24-000069:0
- 160,534 shares0Common StockSEC:0001764013-24-000044:0
- 13,454 shares@ US$36.153.8% of flowCommon StockSEC:0001764013-24-000037:0
- 3,824 shares@ US$38.591.2% of flowCommon StockSEC:0001764013-24-000006:0
- 15,601 shares@ US$32.754.0% of flowCommon StockSEC:0001764013-23-000146:0
- 894 shares@ US$35.540.3% of flowCommon StockSEC:0001764013-23-000117:0
- 50,866 shares@ US$21.978.7% of flowCommon StockSEC:0001764013-23-000107:0
- 91,744 shares@ US$21.3415.3% of flowCommon StockSEC:0001764013-23-000094:0
- 101,339 shares@ US$21.7317.1% of flowCommon StockSEC:0001764013-23-000087:0
- 3,233 shares@ US$19.730.5% of flowCommon StockSEC:0001764013-23-000078:0
25 of 39 declarations
